Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
Key Highlights
- ➤Symvess Q3 sales reached $1.0 million, up 151% from Q2 2026
- ➤Symvess October sales reached $0.8 million as commercial adoption accelerated
- ➤Q4 2026 Symvess sales expected to at least double Q3 sales
- ➤Humacyte plans November 2026 FDA sBLA filing for ATEV dialysis access
- ➤Humacyte initiated Phase 2a CTEV study in coronary artery bypass grafting
- ➤Cash, cash equivalents and restricted cash totaled $64.9 million at September 30
Expert Statements
Laura Niklason, Founder and Chief Executive Officer of Humacyte
“During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second quarter and significantly increasing the number of hospitals ordering Symvess”
Laura Niklason, Founder and Chief Executive Officer of Humacyte
“In our future targeted market in dialysis access, our plan is to file a supplemental BLA for the ATEV in November 2026, supported by results from three Phase 3 studies.”
Laura Niklason, Founder and Chief Executive Officer of Humacyte
“Publication of our V007 Phase 3 results in The Lancet Digital Health and presentation of our V012 Phase 3 results in a late-breaking session at ASN Kidney Week gave the vascular surgery and nephrology communities an overview of the data that will form the basis of our sBLA filing.”
Laura Niklason, Founder and Chief Executive Officer of Humacyte
“These results also support our belief that the ATEV has the potential to address significant unmet needs for dialysis patients seeking improved hemodialysis access options.”
Laura Niklason, Founder and Chief Executive Officer of Humacyte
“Elsewhere in our pipeline, we have initiated our Phase 2a study in coronary artery bypass grafting (CABG) and look forward to enrollment of the first patients.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“Execution of our revamped commercial program for Symvess generated significant momentum during the third quarter,”
Jim Mercadante, Chief Commercial Officer of Humacyte
“Symvess sales revenue for the third quarter was $1.0 million, more than double our results for the second quarter, and achieved the goal we set for the period.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“Momentum has continued into the fourth quarter and based on expanded hospital adoptions and physician engagement, we anticipate at least doubling our third quarter sales revenue in Q4 2026.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“We believe the strategy we’ve established is working and that we have positioned Symvess for sustainable growth throughout the remainder of 2026 and beyond.”
– Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2(nd) quarter.
– Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8 million.
Get started
Create a free account to read the full story.